pharma news today obesity drugs glp-1 october 2025 health Outlook for obesity in 2025: more Alarming rise in weight loss
Description
Will high costs be a barrier to the reach?
Our physician-led medical spa ensures you receive FDA-approved GLP-1 medications and answers 10 FAQs.
Learn about the benefits and practical steps for transitioning patients from GLP-1 RAs to dual GLP-1/GIP receptor agonists, such as tirzepatide, to improve glycemic control in adults with type 2 diabetes.
Conclusions GLP-1 agonists are associated with significant pancreatitis risk which increases with larger cumulative doses.
When patients on GLP-1 therapy also make healthy lifestyle choicesgetting enough sleep and exercising, for examplethe benefits are significantly greater.
